ZEISS introduces MyoActive

Clinical results show highest average efficacy with a spectacle lens to date. ZEISS MyoActive applies Dynamic Signal Theory through patented¹ M.O.V.E. technology.

0.60D less myopia progression achieved with ZEISS MyoActive spectacle lenses on average.²
On average, children wearing ZEISS MyoActive lenses showed no progression of clinical relevance.^2,3
The design uses patented¹ M.O.V.E. technology to generate dynamic signals to reduce adaptation and increase myopia control efficacy.

Aalen, Germany | 1 October 2026 | ZEISS Vision Care

ZEISS Vision Care is introducing ZEISS MyoActive, a new myopia management spectacle lens solution for children to slow myopia progression. The lens design applies the advanced concept of Dynamic Signal Theory through optical defocus. Clinical evidence supports the efficacy of this differentiated approach: At 12 months, ZEISS MyoActive demonstrated the highest efficacy among myopia control spectacle lenses, with 0.60D less myopia progression and 0.22mm less axial elongation than a single vision lens (NCT06563700)⁴. With ZEISS MyoActive, mean progression was -0.23D/year, which is less than the 0.25D increment step used in subjective refraction, indicating no progression of clinical relevance. In addition, 98% fully adapted to the lenses within one week. Results remained consistent across both six-month periods, supporting sustained performance.^2,3

Dynamic Signal Theory

The concept behind ZEISS MyoActive lenses builds on a key challenge in myopia management: the eye and visual system can adapt to repeated, uniform optical signals over time. Dynamic Signal Theory addresses this by combining myopic defocus, which provides the biological signal to help slow eye growth, with dynamic signal variation to help maintain retinal responsiveness. In ZEISS MyoActive lenses, this principle is applied for the first time in a myopia management spectacle lens through patented¹ M.O.V.E. technology.

Optical design and myopia management

The front surface of ZEISS MyoActive combines a central clear zone with patented¹ M.O.V.E. technology which stands for Micro Optical Variable Elements. This non-repetitive layout of microstructures creates continuously changing retinal signals as the eye moves naturally throughout the day. As a result, the optical signal remains active and variable rather than static, helping to reduce visual adaptation. The back surface is optimized using ZEISS ClearFocus design. It minimizes hyperopic defocus in the periphery of the lens.

The combination of a central clear zone and a treatment zone with microstructures, together with the specific back surface design makes ZEISS MyoActive lenses ZEISS’ most effective myopia management lens to date, developed for children.²

Part of the ZEISS Myopia Management Collective

With ZEISS MyoActive, ZEISS Vision Care expands its science-driven myopia management portfolio with another highly effective solution designed for children with myopia. As part of the ZEISS Myopia Management Collective, ZEISS MyoActive is embedded in a broader ecosystem of evidence-based products, solutions, and services, grounded in robust scientific research and continuous innovation. This portfolio is designed to guide eye care professionals across the entire myopia journey and enable effective, sustainable myopia management for younger patients.

ZEISS, ClearFocus Design, MyoActive and M.O.V.E. are trademarks of Carl Zeiss AG and/or other companies of the Carl Zeiss Group.

Not all products, services or offers are approved or offered in every market and approved labelling and instructions may vary from one country to another.

¹
WO 2025/098939 A1
²
Two-year prospective, multi-center, double-blind, randomized controlled clinical trial (NCT06563700) by Shanghai Eye Disease Prevention and Treatment Center, China, 2025. Myopic children aged 7-13 years wearing ZEISS MyoActive (N=56) and myopic children aged 7-13 years wearing ZEISS Single Vision Rx lenses (N=56), one-year results as of July 2026, data on file.
³
Mean progression with ZEISS MyoActive <0.25D which is the smallest measurable change in prescription of clinical relevance.
⁴
The ongoing randomised controlled trial (NCT06563700) enrolled 342 myopic children across three sites in China, assigning them to five test spectacle lens (SPL) designs or a single-vision (SV) control Group.

Press Contact Sarah Kopp

ZEISS Vision Care

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 47,400 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide (March 31, 2026). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Vision Care

ZEISS Vision Care, part of ZEISS Consumer Markets segment, develops and manufactures comprehensive solutions for the entire value chain of ophthalmic optics. The portfolio includes top-quality eyeglass lenses, partner programs, ophthalmic instruments, services, digital solutions and apps for both eye care professionals and consumers, as well as care products for the eye and beyond. As one of the world's leading manufacturers of eyeglass lenses, ZEISS is focused on optimal visual comfort and individualized vision solutions. With a passion for innovation and quality, ZEISS Vision Care is committed to protecting and enhancing people's vision and contributing to lifelong visual health.